New Platform to Lower Barriers to Adoption of Single Cell RNA Sequencing

​ASHG Annual Meeting – Parse Biosciences, a leading provider of accessible and scalable single cell sequencing solutions, announced today a new cloud analysis solution to simplify the analysis of single cell RNA sequencing (scRNA-seq). The new cloud analysis platform will provide an accessible option for researchers to analyze scRNA-seq data without required bioinformatics experience.

When compared to bulk RNA sequencing methods, scRNA-seq provides researchers with more complete representations of biological systems and has applications across broad research fields including developmental biology, oncology, and immunology. The increasing adoption rate and scale of scRNA-seq requires more accessible data analysis approaches that deliver sophisticated results without in-house informatic infrastructure.

The new solution is a direct result of a co-development collaboration between Parse Biosciences and DNAnexus, the leading provider of cloud-based genomic and biomedical data access and companion analysis software. The Parse Biosciences platform is built on top of the proven DNAnexus technology, which allows researchers to access, analyze, and share scRNA-seq data to help advance scientific discovery. The protected environment was designed to meet the most rigorous standards for data quality, scalability, security, privacy, and safety.

“We are thrilled to announce this cloud analysis software, making our single cell solution even easier to adopt,” said Alex Rosenberg, CEO of Parse Biosciences. “This approach continues to deliver on the commitment to our customers and the broader single cell community, to provide the simplest and most scalable approach to single cell sequencing.”

Parse Biosciences will be discussing the capabilities of its technology at this year’s American Society of Human Genetics Meeting from October 25-29, 2022. CTO and co-founder Charlie Roco will present on the new analysis solution along with the Evercode WT v2 chemistry at his CoLab session titled “Democratizing Access to Single Cell RNA Sequencing,” on Wednesday, October 26 at 3:45 PM in Theater 1.

About Parse Biosciences

Parse Biosciences is a Seattle-based company with the mission of accelerating progress in human health and scientific research. At the core of our company is our pioneering approach for single cell sequencing. Single-cell sequencing has already enabled groundbreaking discoveries which have led to new understandings of cancer treatment, tissue repair, stem cell therapy, kidney and liver disease, brain development, and the immune system. At Parse Biosciences, we are providing researchers with the ability to perform single cell sequencing with unprecedented scale and ease. To learn more, please visit: https://www.parsebiosciences.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20221026005427/en/